Trial Profile

A Phase III Clinical Trial of AMT901 for the Treatment of HER2-Positive Breast Cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 17 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary)
Indications Breast cancer; HER2 positive breast cancer
Focus Registrational; Therapeutic Use
Sponsors AffaMed Therapeutics

Most Recent Events

17 Dec 2019 New trial record
10 Dec 2019 According to an AffaMed Therapeutics media release, the company has received Clinical Trial Application (CTA) approval from the China National Medical Products Administration (NMPA) to conduct clinical trials for AMT901, or SB3, a biosimilar for Herceptin (trastuzumab).Clinical study preparation is on track and first patient visit is scheduled in Q1 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com